By Fatskills Exam Guides Team — the exam nerds behind 28,500+ quizzes and 2.1M practice questions across 500+ global exams.
Immunosuppressants: Cyclosporine, Tacrolimus, Mycophenolate, Steroids
Immunosuppressants are high-yield for Step 1 and Step 2 CK, particularly in the context of organ transplantation, autoimmune diseases, and immunodeficiency. You'll see these medications in basic science, clinical, and management contexts.
Missing a life-threatening complication (e.g., GVHD, malignancy) can be fatal.
Exam board insight: The examiners emphasize the importance of monitoring and dose adjustments.
The mistake: Failing to consider the potential complications of immunosuppression.
Question 1: A 35-year-old patient with a history of kidney transplantation presents with elevated creatinine levels. Which of the following is the most likely cause? Options: A) tacrolimus toxicity, B) infection, C) autoimmune disease flares, D) GVHD Answer: A) tacrolimus toxicity Explanation: The patient's elevated creatinine levels are most likely due to tacrolimus toxicity, which is a common complication of immunosuppression.
Question 2: A 45-year-old patient with a history of autoimmune disease presents with a flare of symptoms. Which of the following is the most appropriate treatment? Options: A) steroids, B) cyclosporine, C) tacrolimus, D) mycophenolate Answer: A) steroids Explanation: The patient's autoimmune disease flare is most appropriately treated with steroids, which are a first-line treatment for autoimmune disease flares.
Question 3: A 30-year-old patient with a history of kidney transplantation presents with symptoms of infection. Which of the following is the most likely cause? Options: A) infection, B) autoimmune disease flares, C) GVHD, D) tacrolimus toxicity Answer: A) infection Explanation: The patient's symptoms of infection are most likely due to an infection, which is a common complication of immunosuppression.
Join 4M+ learners. Unlock unlimited quizzes, wrong-answer tracking, flashcards + reminders, study guides, and 1-on-1 challenges.